Showing posts with label trials. Show all posts
Showing posts with label trials. Show all posts

Thursday, May 1, 2025

Roche’s First-in-Class Werner Helicase Inhibitor Shows Early Promise in Phase I Cancer Trial

   

    In a meeting at the American Association for Cancer Research (AACR) Annual Meeting 2025, principal investigator Timothy Yap, M.B.B.S., Ph.D., has published the results of RO758931, a first-in-class drug that inhibits the WRN helicase, a protein essential for survival in certain cancers.

    Although target therapy is the first in a new class of drugs, it is part of a wider group of therapies targeting the DNA damage response for patients with solid tumors and genetic changes known as high microsatellite instability (MSI) or deficient mismatch repair (dMMR). These can occur in many cancer types, and most patients who have these types of solid tumors do not respond to immune checkpoint inhibitors or develop resistance during treatment. Dr, Timothy Yap states:

"RO7589831 appears generally safe and shows promising signals of anti-tumor efficacy. These are encouraging early clinical data, especially because this is a patient population that currently has very limited treatment options. This also further validates Werner helicase as an actionable target, which is exciting because many cancers are highly dependent on it for survival."

    Like other DNA damage response therapies, RO7589831 inhibits the DNA repair enzyme, Werner helicase, preventing it from working properly. This creates a buildup of DNA damage within tumor cells, leading to cell death. However, since normal cells lack MSI, they will not be affected. 

    44 patients were evaluated for safety. Most experienced mild to moderate adverse effects. The most frequent side effects are manageable and similar to those of other treatments. They include nausea, vomiting, and diarrhea. While higher doses are less tolerable, no dose-limiting toxicities were observed. Three randomized dose-level cohorts are underway to establish the optimal recommended dose for the Phase II trial in the future. 

WORKS CITED

 MBT Desk (2025). Roche’s First-in-Class Werner Helicase Inhibitor Shows Early Promise in Phase I Cancer Trial. MedBoundTimes. https://www.medboundtimes.com/biotechnology/roches-first-in-class-werner-helicase-inhibitor-phase-i-cancer-trial

Genentech (2025). A clinical trial to look at how safe and well RO7589831 works at different doses in people with advanced solid tumours, and how the body processes RO7589831. https://genentech-clinicaltrials.com/en/trials/cancer/solid-tumors/a-study-to-evaluate-the-safety--pharmacokinetics--and-a-03859.html

Saturday, November 28, 2020

A genetic link to predict Alzheimers disease

 


Scientists at Tufts University School of Medicine came across a pattern while researching Alzheimers disease. Their initial goal was to find mechanisms that result in Alzheimers over time but are undetectable because of their lack of symptoms in the beginning. They scientists found a mechanism in the brain that causes a traffic jam of enzymes. This mechanism is found to be a product of a genetic mutation. Which increases the amount of amyloid beta. Which is a big cause of Alzheimers disease. This is a very big find for the medical community because it has been very hard to predict Alzheimers up until recently. This is mainly due to the lack of symptoms until it is too late or untreatable. However with this new discovery it may be possibly to detect the onset of Alzheimers years in advance due to the discovery of this mechanism in the neurons of the brain. Treating this mechanism early has show in experiments to prove some help to delaying or protecting against the disease. However In the late stages of this mechanism treatment has offered no help. This is still all in trials and still being researched however, so there is still hope from this trial to have an even more massive breakthrough. (staff)


Source: staff, Science X. “Found: A Genetic Link to Molecular Events That Precede Symptoms in Alzheimer's Disease.” Medical Xpress - Medical Research Advances and Health News, Medical Xpress, 18 Nov. 2020, medicalxpress.com/news/2020-11-genetic-link-molecular-events-symptoms.html. 

Links used: 

https://medicalxpress.com/news/2020-11-genetic-link-molecular-events-symptoms.html

https://stm.sciencemag.org/content/12/570/eaba1871



Friday, March 31, 2017

Reversing the Aging Process?!


 In more recent times, researchers have began reseting the clock in mice.


 This deals with erasing the epigenomic marks by activating genes responsible for the health of embryonic cells. Scientists have rejuvenated the organs of mice and discovered that they can lengthen their lifespan by 30%! This technique cannot be applied to humans but scientists are well on their way to gaining a better understanding of muscle and organ regeneration. I believe this is an incredible finding! Whether we are either slowing down or reversing aging we are moving forward scientifically and I find that amazing. This is all stemming from work completed ten years ago and I cannot wait to see how this has advanced in ten years to come.

https://www.nytimes.com/2016/12/15/science/scientists-say-they-can-reset-clock-of-aging-for-mice-at-least.htmlrref=collection%2Ftimestopic%2FGenetic%20Engineering&action=click&contentCollection=science&region=stream&module=stream_unit&version=latest&contentPlacement=4&pgtype=collection 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3839659/